Showing results (791-800 of 802) with videos related to

Sort By:
Pageof 81
Molecular Cancer Therapeutics|March 26, 2017
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family InhibitorTimothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, et al.
The Lancet. Haematology|February 8, 2024
Diagnosis and management of pyruvate kinase deficiency: international expert guidelinesHanny Al-Samkari, Nadine Shehata, Kelly Lang-Robertson, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2026
Metallothionein loss in cancer cells contributes to increased mutations through defective DNA repair and metabolic imbalanceMirna Mina-Abouda, Amy C Rees, Della Evans, et al.
Journal of Medicinal Chemistry|April 9, 2026
From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug DesignXiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Hepatology (Baltimore, Md.)|September 13, 2019
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent AttacksLaurent Gouya, Paolo Ventura, Manisha Balwani, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 InhibitorsYoung Shin Cho, Hayley Angove, Christopher Brain, et al.
Medrxiv : the Preprint Server for Health Sciences|January 5, 2021
Neutralising antibodies in Spike mediated SARS-CoV-2 adaptationS A Kemp, D A Collier, R Datir, et al.
The New England Journal of Medicine|June 11, 2020
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaManisha Balwani, Eliane Sardh, Paolo Ventura, et al.
Journal of Medicinal Chemistry|May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Pageof 81